Indian Army Insulin Injection Tender 100 IU/ml 3 ml Vials 2026
Progress
Quantity
1450
Category
Inj Isulin Glargin Rec DNA 100 IU per ml vial of 3 ml
Bid Type
Two Packet Bid
Tender Overview
The procurement is for multiple insulin injections by the Indian Army under the Department Of Military Affairs. The items include 100 IU per ml vials of 3 ml for several insulin products, intended for cold-chain supply. The contract requires OEM authorization certificates and batch-wise QA reports, with delivery via refrigerated vans. Proximity of supplying vendors is favored due to cold-chain constraints. The terms allow quantity variation up to 25% during both initial and currency periods, at contracted rates. The data indicates a high-priority medical supply with strict cold storage and traceability requirements.
Technical Specifications & Requirements
- Product names include: Inj Insulin Glargine Rec DNA 100 IU per ml vial of 3 ml, Inj Insulin Aspart plus Protamine 100 IU per ml vial of 3 ml, Inj Degludeg Insulin 100 IU per ml vial of 3 ml, Inj Degludeg Insulin plus Aspart Ryzodeg 100 IU per ml vial of 3 ml, Inj Apidra Glulisine 100 IU per ml vial of 3 ml, Inj Insulin Lispro Rec DNA 100 IU per ml vial of 3 ml.
- Delivery mode: refrigerated van only; cold chain mandatory; priority to nearby suppliers.
- Documentation required at bid submission: OEM authorization certificate; batch-wise QA reports for each injection; packaging and labeling compliance; evidence of cold-chain capability.
- Volume/quantity: not disclosed; quantity adjustment up to 25% of bid quantity; extension of delivery period proportionally calculated with a minimum of 30 days.
- Standards/quality: (not specified in the data); emphasis on authenticity, cold-chain compliance, and batch traceability.
- Delivery timelines: based on last delivery order date; extended period calculations apply under option clause.
Terms, Conditions & Eligibility
- EMD/security deposit: not disclosed in data; bidders should seek explicit amount in tender document.
- Delivery: quantity may be increased up to 25% during contract; delivery period adjusts accordingly with minimum 30 days.
- Payment terms: not specified in the provided data.
- Documents required: OEM authorization; batch-wise QA reports; evidence of cold-chain capability; vendor proximity details.
- Penalties/warranty: not specified; emphasis on timely refrigerated delivery and batch traceability.
- Eligibility: must demonstrate cold-chain logistics capability; likely preference for near-by suppliers; compliance with OEM documentation.
Key Specifications
-
Insulin products: 100 IU/ml in 3 ml vials
-
Items listed: Glargine Rec DNA, Aspart plus Protamine, Degludeg Insulin, Degludeg Insulin plus Aspart (Ryzodeg), Apidra Glulisine, Lispro Rec DNA
-
Delivery: refrigerated van only; cold chain maintained at all times
-
Certification: OEM authorization certificate; batch-wise QA reports
-
Quantity adjustment: ±25% of bid quantity; extended delivery period rules apply
Terms & Conditions
-
Mandatory cold-chain logistics with refrigerated transport
-
OEM authorization certificates and batch-wise QA reports required
-
Quantity may be increased up to 25% during contract and currency
-
Nearby supplier priority due to cold-chain constraints
-
Delivery schedule linked to last delivery order date with minimum 30 days
Important Clauses
Delivery Terms
Delivery must be via refrigerated van; cold chain maintained; delivery period adjusts with option clause; minimum additional time 30 days.
Quantity Flexibility
Up to 25% increase in bid quantity at contracted rates during initial and currency period; delivery time recalculated accordingly.
Documentation
OEM authorization certificates and batch-wise QA reports for each injection must be uploaded at bid submission.
Bidder Eligibility
-
Demonstrate cold-chain logistics capability with refrigerated transport
-
Provide OEM authorization certificate for each insulin product
-
Submit batch-wise QA reports covering all listed insulin injections
Additional Tender Data
Commercial Details
Tender Category
Goods
Bid To RA
No
Bid To RA Enabled
No
Item Category
Inj Isulin Glargin Rec DNA 100 IU per ml vial of 3 ml , Inj Insulin Aspart plus Protamine 100 IU per ml vial of 3 ml , Inj Degludeg Insulin 100 IU per ml vial of 3 ml , Inj Degludeg Insulin plus Aspart Ryzodeg 100 IU per ml vial of 3 ml , Inj Apidra Glulisine 100 IU per ml vial of 3 ml , Inj Insulin Lispro Rec DNA 100 IU per ml vial of 3 ml
Delivery Details
Max Delivery Days
15
Delivery Locations
1
Delivery Cities
Faridkot
Delivery Locations
| Consignee | Address | City | State | Pincode | Quantity | Delivery Days | Additional Requirement |
|---|---|---|---|---|---|---|---|
| - | Faridkot | Faridkot | - | - | 500 | 15 | - |
Authority Records
BID & GeM Expert Consultancy
End-to-end support — bid preparation, GeM registration, document filing & compliance by industry experts.
Free consultation · 24h response
Documents 4
GeM-Bidding-9558456.pdf
Main Document
BOQ Document
BOQ
BOQ Document
BOQ
GEM General Terms and Conditions Document
GEM_GENERAL_TERMS_AND_CONDITIONS
Bill of Quantities (BOQ)
6 Items Sign in to view GEM price trends Sign in for GEM prices
Inj Isulin Glargin Rec DNA 100 IU per ml vial of 3 ml
Inj
Inj Insulin Aspart plus Protamine 100 IU per ml vial of 3 ml
Inj
Inj Degludeg Insulin 100 IU per ml vial of 3 ml
Inj
Inj Degludeg Insulin plus Aspart Ryzodeg 100 IU per ml vial of 3 ml
Inj
Inj Apidra Glulisine 100 IU per ml vial of 3 ml
inj
Inj Insulin Lispro Rec DNA 100 IU per ml vial of 3 ml
inj
| Item # | Title | Description | Quantity | Unit | Consignee | Delivery (Days) | Price Trends |
|---|---|---|---|---|---|---|---|
| 1 | Inj Isulin Glargin Rec DNA 100 IU per ml vial of 3 ml | Inj | 500 | pfs | [email protected] | 15 | |
| 2 | Inj Insulin Aspart plus Protamine 100 IU per ml vial of 3 ml | Inj | 50 | pfs | [email protected] | 15 | |
| 3 | Inj Degludeg Insulin 100 IU per ml vial of 3 ml | Inj | 100 | pfs | [email protected] | 15 | |
| 4 | Inj Degludeg Insulin plus Aspart Ryzodeg 100 IU per ml vial of 3 ml | Inj | 500 | pfs | [email protected] | 15 | |
| 5 | Inj Apidra Glulisine 100 IU per ml vial of 3 ml | inj | 100 | pfs | [email protected] | 15 | |
| 6 | Inj Insulin Lispro Rec DNA 100 IU per ml vial of 3 ml | inj | 200 | pfs | [email protected] | 15 |
🤖 AI-Powered Bidder Prediction
Discover companies most likely to bid on this tender
Required Documents
GST certificate
PAN card
OEM authorization certificate
Batch-wise QA reports for each insulin product
Evidence of cold-chain logistics capabilities
Proof of refrigerated transport arrangement (refrigerated van)
Company financial statements (as applicable)
Any prior similar supply experience certificates
Frequently Asked Questions
How to bid for insulin injection tender in India Army 2026
Bidders must provide OEM authorization certificates and batch-wise QA reports for each insulin product, demonstrate cold-chain capability, and upload evidence of refrigerated transport. Ensure compliance with the option clause allowing up to 25% quantity variation and submit all required documents (GST, PAN, financials) as per Terms.
What documents are required for insulin tender in Army procurement
Required documents include OEM authorization certificates, batch-wise QA reports, GST registration, PAN card, evidence of refrigerated transport capability, and prior experience certificates. Upload these with the bid to prove authenticity, traceability, and cold-chain compliance for all six insulin products.
What are the technical specifications for insulin vials in this tender
Products are 100 IU/ml in 3 ml vials across six insulin types: Glargine Rec DNA, Aspart plus Protamine, Degludeg, Degludeg plus Aspart (Ryzodeg), Apidra Glulisine, Lispro Rec DNA. Delivery must be through a fully refrigerated supply chain with batch-wise QA reporting.
When is delivery expected under the option clause for quantity changes
Delivery periods can be adjusted when quantity changes are exercised up to 25% of the bid quantity. The new delivery time is calculated as (increased quantity ÷ original quantity) × original delivery period, with a minimum of 30 days unless the original exceeds that.
What are the near-by supplier priority requirements for cold chain
Priority is given to nearby suppliers to maintain cold-chain integrity, reducing transit time. Vendors must demonstrate proximity, validated cold-storage facilities, and transport routes to ensure continuous refrigerated conditions during transit and storage.
What is required to prove OEM authorization for insulin products
Submit OEM authorization certificates for all six insulin products and provide batch-wise QA reports. Ensure certificates are current and match product names exactly as listed in the BOQ to verify legitimate sourcing and regulatory compliance.
What is the delivery method for insulin injections in this tender
Delivery must be exclusively via refrigerated vans with maintained cold chain. Suppliers should have certified cold-chain logistics, temperature monitoring, and rapid transit arrangements to ensure intact product quality at delivery points.
How to verify batch-wise QA reports for insulin products
Batch-wise QA reports must accompany each product listing, showing lot numbers, manufacturing dates, expiry dates, and conformity to product specifications. Reports should align with OEM data and be uploaded in the bid submission package.
Explore More Opportunities
Unlock Tender Documents
Sign up now to access all documents
Documents 4
GeM-Bidding-9558456.pdf
Main Document
BOQ Document
BOQ
BOQ Document
BOQ
GEM General Terms and Conditions Document
GEM_GENERAL_TERMS_AND_CONDITIONS